文献速递结核与非结核分枝杆菌

曲格列酮通过LKB1-AMPKα信号通路经巨噬细胞自噬减少结核分枝杆菌胞内存活

Troglitazone Reduction of Intracellular Mycobacterium tuberculosis Survival Via Macrophage Autophagy Through LKB1-AMPKα Signaling.
PubMed 文献 · J Infect Dis · 2025-01-01

本研究检测了3种降糖药的抗结核分枝杆菌(Mtb)效果,仅曲格列酮(Trog)在体外和体内增强抗分枝杆菌作用,机制为Trog通过靶向STRADA促进LKB1磷酸化激活,经LKB1-AMPK信号通路激活自噬。Trog抑制临床异烟肼耐药Mtb的胞内存活,与异烟肼联用对Mtb H37Rv呈相加抗菌效应。

要点

  • 3种降糖药中仅曲格列酮在体外和体内增强抗Mtb效果,机制为激活自噬。
  • 曲格列酮经靶向STRADA促进LKB1磷酸化,通过LKB1-AMPK通路激活自噬。
  • 曲格列酮抑制临床异烟肼耐药Mtb胞内存活,与异烟肼联用对H37Rv呈相加效应。

核心结论

  • 降糖药曲格列酮可能被重新定位为宿主导向治疗的候选药物,并与一线抗结核药物联用。

研究设计与样本

  • 检测3种降糖药的抗Mtb效果,行体外和体内实验、敲低实验、分子对接和免疫共沉淀实验。

主要发现

  • 3种降糖药中仅曲格列酮在体外和体内增强抗分枝杆菌效果,源于曲格列酮介导的自噬激活。
  • 敲低实验显示曲格列酮通过LKB1-AMPK信号通路激活自噬并发挥抗分枝杆菌活性。
  • 分子对接和免疫共沉淀实验显示曲格列酮通过靶向STRADA促进LKB1磷酸化和激活。
  • 曲格列酮抑制临床异烟肼耐药Mtb的胞内存活,曲格列酮与异烟肼联用对Mtb H37Rv呈相加抗菌效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tuberculosis caused by Mycobacterium tuberculosis (Mtb), results in significant disease and death worldwide. Host-directed therapy, including conventional drugs, is a promising antituberculosis strategy that shows synergistic antibacterial effects when combined with antituberculosis drugs. Here, the mycobactericidal effect of 3 antidiabetic drugs was examined. Of these, only troglitazone (Trog) enhanced the antimycobacterial effect in vitro and in vivo. This was due to Trog-mediated autophagy activation. Moreover, a knock-down experiment revealed that Trog activated autophagy and exhibited antimycobacterial activity through the serine/threonine-protein kinase STK11 (LKB1)-5'-AMP-activated protein kinase (AMPK) signaling pathway. Molecular docking and coimmunoprecipitation experiments demonstrated that Trog promoted LKB1 phosphorylation and activation by targeting STE20-related kinase adapter protein alpha (STRADA). Finally, we found that Trog inhibited the intracellular survival of clinical isoniazid-resistant Mtb, and the combination of Trog and isoniazid showed additive antibacterial effects against Mtb H37Rv. Taken together, antidiabetic Trog may be repurposed as a candidate for host-directed therapy and combined with first-line antituberculosis drugs.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Bi J, Guo Q, Gong Y, et al. Troglitazone Reduction of Intracellular Mycobacterium tuberculosis Survival Via Macrophage Autophagy Through LKB1-AMPKα Signaling. J Infect Dis. 2025. PMID: 39450555. doi:10.1093/infdis/jiae523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。